Teva Pharmaceutical Industries Ltd

$ 15.14 0.14 (0.93%)
Volume: 7,353,362 Avg Vol (1m): 10,803,617
Market Cap $: 16.74 Bil Enterprise Value $: 44.96 Bil
P/E (TTM): 0.00 P/B: 1.07
Earnings Power Value 26.74
Net Current Asset Value -31.18
Tangible Book -23.46
Projected FCF 41.57
Median P/S Value 40.26
Graham Number 0
Peter Lynch Value 0
DCF (FCF Based) 0
DCF (Earnings Based) 0
YTD (-%)

Financial Strength : 4/10

Current vs industry vs history
Cash-to-Debt 0.06
Equity-to-Asset 0.24
Debt-to-Equity 1.97
Debt-to-EBITDA 174.19
Interest Coverage 3.36
Piotroski F-Score 5
0
1
2
3
4
5
6
7
8
9
Altman Z-Score 0.28
DISTRESS
GREY
SAFE
Beneish M-Score -2.60
Not Manipulator
Manipulator

Profitability & Growth : 5/10

Current vs industry vs history
Operating Margin % 16.38
Net Margin % -11.40
ROE % -13.89
ROA % -3.23
ROC (Joel Greenblatt) % -23.01
3-Year Total Revenue Growth Rate -1.40
3-Year Total EBITDA Growth Rate -65.20
N/A

» TEVA's 30-Y Financials

Financials (Next Earnings Date: 2019-05-02)

Guru Trades Click for details

» Details

Insider Trades

SEC Filings

Gurus Latest Trades with NYSE:TEVA

» Interactive Chart

Peter Lynch Chart

Business Description

Industry Drug Manufacturers » Drug Manufacturers - Specialty & Generic    NAICS : 325412    SIC : 0
Compare SHSE:600518 TSE:4507 NSE:SUNPHARMA SZSE:000538 TSE:4523 SHSE:600196 NAS:MYL XPAR:IPN OCSE:LUN NYSE:PRGO TSE:4508 SZSE:000963 XSWX:VIFN SZSE:300122 JSE:APN SHSE:600332 HKSE:03320 SHSE:600085 TSE:4581 SHSE:600535
Traded in other countries TEV.Germany TEVAN.Mexico
Address 5 Basel Street, Petach Tikva, ISR, 4951033
Headquartered in Israel, Teva Pharmaceutical is the world's largest generic pharmaceutical manufacturer. The company also develops and sells branded pharmaceuticals in central nervous system, oncology, respiratory, and women's health categories. After acquiring Allergan's generics business, Teva's generic sales should be over 60% of total revenue, with branded drug and international over-the-counter revenue making up the balance of sales. Copaxone makes up about half of Teva's branded drug segment, with about $4 billion in sales for 2015.

Ratios

Current vs industry vs history
Forward PE Ratio 6.37
N/A
PB Ratio 1.07
PS Ratio 0.86
Price-to-Free-Cash-Flow 8.73
Price-to-Operating-Cash-Flow 6.41
EV-to-EBIT -26.41
EV-to-EBITDA 266.63
EV-to-Revenue 2.36
Shiller PE Ratio 136.31
Current Ratio 0.96
Quick Ratio 0.63
Days Inventory 170.12
Days Sales Outstanding 112.71
Days Payable 64.06

Dividend & Buy Back

Current vs industry vs history
3-Year Dividend Growth Rate (Per Share) -100.00
N/A
3-Year Share Buyback Rate -3.90

Valuation & Return

Current vs industry vs history
Price-to-Projected-FCF 0.36
Price-to-Median-PS-Value 0.38
Earnings Yield (Joel Greenblatt) % -3.80
Forward Rate of Return (Yacktman) % 21.93

More Statistics

Revenue (TTM) (Mil) $ 18,854
EPS (TTM) $ -2.33
Beta 2.09
Volatility % 53.88
52-Week Range $ 14.04 - 25.96
Shares Outstanding (Mil) 1,091.6

Analyst Estimate

Piotroski F-Score Details

Piotroski F-Score 5
Positive ROA N
Positive CFROA Y
Higher ROA yoy Y
CFROA > ROA Y
Lower Leverage yoy N
Higher Current Ratio yoy Y
Less Shares Outstanding yoy N
Higher Gross Margin yoy N
Higher Asset Turnover yoy Y